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Abstract: About one third of patients with epilepsy are refractory to medical treatment. For 
these patients, alternative treatment options include implantable neurostimulation devices 
such as vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neuro-
stimulation systems (RNS). We conducted a systematic literature review to assess the available 
evidence on the clinical efficacy of these devices in patients with refractory epilepsy across 
their lifespan. VNS has the largest evidence base, and numerous randomized controlled trials 
and open-label studies support its use in the treatment of refractory epilepsy. It was approved 
by the US Food and Drug Administration in 1997 for treatment of partial seizures, but has also 
shown significant benefit in the treatment of generalized seizures. Results in adult populations 
have been more encouraging than in pediatric populations, where more studies are required. 
VNS is considered a safe and well-tolerated treatment, and serious side effects are rare. DBS is 
a well-established treatment for several movement disorders, and has a small evidence base for 
treatment of refractory epilepsy. Stimulation of the anterior nucleus of the thalamus has shown 
the most encouraging results, where significant decreases in seizure frequency were reported. 
Other potential targets include the centromedian thalamic nucleus, hippocampus, cerebellum, 
and basal ganglia structures. Preliminary results on RNS, new-generation implantable neuro-
stimulation devices which stimulate brain structures only when epileptic activity is detected, are 
encouraging. Overall, implantable neurostimulation devices appear to be a safe and beneficial 
treatment option for patients in whom medical treatment has failed to adequately control their 
epilepsy. Further large-scale randomized controlled trials are required to provide a sufficient 
evidence base for the inclusion of DBS and RNS in clinical guidelines.
Keywords: deep brain stimulation, epilepsy, implantable neurostimulation device, responsive 
neurostimulation, seizures, vagus nerve stimulation
Background
Epilepsy is a common neurological disorder affecting approximately 50 million people 
worldwide, and is associated with considerable morbidity and mortality.1 Epilepsy is 
defined as a predisposition to experience seizures as a result of abnormal (excessive 
or hypersynchronous) neuronal activity in the brain.2 Seizures are classified as partial 
(focal) or generalized, depending on the extent to which they affect the brain.3 The 
majority of patients are diagnosed with idiopathic epilepsy (where a structural cause 
cannot be found), whereas the remaining are described as symptomatic, and may be 
the result of structural abnormalities, such as tumor, stroke, head injury, or infection. 
These definitions are undergoing a significant review in the light of new concepts that 
have emerged from recent research, such as that of “network epilepsy”, which has 
challenged the traditional dichotomy between partial/focal and generalized epilepsy.4 
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Antiepileptic drugs (AEDs) are the mainstay of treatment 
for epilepsy. Seizure freedom is achieved in around 50% of 
patients with the first trial of pharmacotherapy, and this is 
increased with add-on medications.5 Unfortunately AEDs can 
have suboptimal tolerability profiles, especially with regard 
to behavioral6,7 and cognitive8,9 aspects. When a patient fails 
to respond to adequate trials of two AEDs because of poor 
efficacy and/or tolerability, a diagnosis of “treatment resis-
tant” or “refractory” epilepsy is formulated.10 This occurs 
in up to one-third of patients with epilepsy.11 In such cases, 
other treatments are available, including novel AEDs, keto-
genic diet, epilepsy surgery, and more recently, implantable 
neurostimulation devices.11
Three types of implantable neurostimulation devices 
have been introduced and approved for the management of 
refractory epilepsy: vagus nerve stimulation (VNS), deep 
brain stimulation (DBS), and responsive neurostimulation 
systems (RNSs). After considering the background and 
proposed mechanisms of action of each of these, we will 
review the available evidence about their clinical efficacy, 
safety, and tolerability.
Methods
We conducted a systematic literature search on the PubMed 
and PsycInfo databases, and retrieved all randomized con-
trolled trials (RCTs) assessing the clinical efficacy of the 
implantable neurostimulation devices (VNS, DBS, and 
RNS). Open-label studies assessing clinical efficacy were 
also included; however, due to large numbers of low-powered 
studies in the VNS literature, selection criteria were applied. 
Studies were excluded if they focused on experimental/
molecular models, were published in languages other than 
English, did not report seizure reduction and/or response rates 
($50% reduction in seizures), or if they were conducted on 
sample sizes smaller than 50 patients. Case reports, letters to 
the editor, conference abstracts, and commentaries were also 
excluded. Finally, reference lists from recent review articles 
were also scanned for further relevant studies.
VNS
VNS is an invasive extracranial neurostimulation technique 
involving implantation of a device at the level of the subcla-
vian region. Two or three leads are woven around the left 
vagus nerve and connected to a generator producing electrical 
impulses that modulate the signals conducted by its afferent 
fibers. While the electrical test of the device is performed 
intraoperatively, the device tends to be activated only 1 to 
2 weeks postoperatively, often at the first outpatient follow-up. 
The exact mechanism by which VNS reduces seizure activity 
is unknown, although several models have been proposed. In 
particular, it has been suggested that VNS works by increasing 
cerebral blood flow and activating neuronal networks in the 
thalamus and other deep brain structures. A potential role for 
norepinephrine has also been postulated.12
VNS was approved by the US Food and Drug Administra-
tion in 1997 as adjunctive treatment in patients over 12 years 
of age with partial-onset seizures which are refractory to 
AED treatment. VNS is also approved for use in the treat-
ment of resistant depression and studies are being undertaken 
assessing its efficacy in a number of other neurological and 
psychiatric disorders.13
The earliest trials in humans assessing the effect of VNS 
on seizure outcome in patients with refractory epilepsy were 
published in the early 1990s, and their encouraging results 
prompted two large RCTs (Table 1) to build an evidence 
base for its safety and efficacy.
Adult populations
The first RCT was undertaken by The Vagus Nerve Stimu-
lation Study Group, and published in 1995.14 The trial was 
conducted in 17 centers across North America and Europe, 
and recruited 114 patients with medically intractable seizures 
and a wide range of seizure types, who were taking, on aver-
age, two AEDs. This study compared efficacy of VNS at high 
levels versus low stimulation intensity. Patients were blinded 
to their stimulation setting, as was the investigator respon-
sible for data collection. Each patient received a 14-week 
trial of VNS, after which their seizure frequency was com-
pared to baseline. In the group receiving high-intensity VNS 
(presumed therapeutic dose), seizure frequency was reduced 
by 25%, from a median 0.73 seizures per day at baseline 
to 0.42 seizures per day after stimulation. Furthermore, a 
responder rate of 31% was observed. In the group receiving 
low-intensity VNS (presumed sub-therapeutic dose), seizure 
frequency was reduced by 6% (from 0.82 seizures per day 
to 0.80 seizures per day) and a responder rate of 13% was 
observed. The results of this study confirmed the preliminary 
findings from smaller open-label studies, and the authors con-
cluded that chronic intermittent left vagus nerve stimulation 
might be an effective treatment for patients with medically 
intractable seizures who are not candidates for resective 
epilepsy surgery.
The second RCT was carried out and published in 1998, 
looking specifically at the use of VNS in the management of 
partial-onset seizures.15 A total of 192 patients were random-
ized to receive either high- or low-level chronic VNS, and Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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were followed-up for a minimum of 3 months. In the group 
receiving high-level VNS, median seizure frequency was 
0.58 seizures per day, which was reduced by 28%, compared 
to 15% in the group receiving low-level VNS (P=0.04). 
Patients from this study were followed-up as part of a long-
term prospective study,16 where all patients received high-
level VNS. At 12 months post-implantation, median seizure 
reduction was 45%, and responder rate was 35%.
The results of a follow-up study of 440 patients from five 
clinical trials, including the two RCTs, were published in 
1999.17 At baseline, patients had an average of 1.73 seizures 
per day, and average disease duration was over 20 years. 
Responder rates were 37% at 1 year, 43% at 2 years, and 
43% at 3 years. The efficacy of VNS as a long-term treat-
ment for refractory epilepsy was confirmed by the long-term 
data. A large number of open-label studies have since been 
undertaken, looking at the efficacy and safety of VNS as a 
treatment for different seizure types across several patient 
populations, including both adults and children. Seven stud-
ies looked at VNS as a treatment of refractory epilepsy in 
predominantly adult populations. Responder rates ranged 
between 64%18 and 36%,19 although some smaller studies 
reported rates as high as 86%20 and as low as 10%.21 The 
largest study to date was undertaken in 2008, and retrospec-
tively analyzed data collected in the VNS therapy patient 
outcome registry.22 The authors compared VNS treatment 
in patients who had previously undergone cranial surgery to 
those who had not. Responder rates for the cranial surgery 
group were 55%, compared to 62% in the group who had 
not had surgery. The authors concluded that VNS may be 
an effective palliative therapy where cranial surgery had 
previously failed, although it was more beneficial in those 
who had not undergone surgery.
Other studies compared the effectiveness of VNS for dif-
ferent seizure types, with mixed results. A recent multicenter 
trial in Israel23 found that VNS was most effective in partial 
seizures, where the responder rate was 52%, compared to 43% 
for the whole cohort. The results also showed that VNS was 
more effective in reducing seizure frequency in patients over 
the age of 21. However, a previous study of 165 patients19 
reported higher responder rates in idiopathic generalized 
epilepsies (57%) compared to partial epilepsies (47%) or 
symptomatic generalized epilepsies (46%). In most of the 
reviewed studies, seizure frequency was recorded between 
12 and 24 months post-implantation. Moreover, the duration 
of follow-up tended to correlate positively with the responder 
rate. One retrospective study18 recorded seizure frequency in 
65 patients who had received VNS therapy over 10 years, 
and found a responder rate of 86% and a mean decrease 
in seizure frequency of 76%. The efficacy of VNS as an 
Table 1 Randomized controlled trials for vagus nerve stimulation (vNS) in patients with refractory epilepsy
Study Study type Participants Study protocol  Measure of effect (%)
The vagus Nerve 
Stimulation Study 
Group, 199514
Double-blind 
randomized 
controlled trial 
114 patients 
$12 years old 
with refractory 
seizures
Patients were 
randomized to 
receive 14 weeks 
of high- or 
low-level vNS 
stimulation
High-level stimulation
Responder rate =31
Decrease in seizure frequency =25
Seizure freedom =0
Low-level stimulation
Responder rate =13
Decrease in seizure frequency =6
Seizure freedom =0
Handforth et al 
199815
Double-blind 
randomized 
controlled trial
192 patients aged 
13–60 years old 
with refractory 
partial-onset 
seizures
Patients were 
randomized 
to receive a 
minimum of 
3 months of  
high- or low-level 
vNS stimulation
High-level stimulation
Responder rate = not reported
Decrease in seizure frequency =28
Seizure freedom = not reported
Low-level stimulation
Responder rate = not reported
Decrease in seizure frequency =15
Seizure freedom = not reported
Klinkenberg et al 
201228
Double-blind 
randomized 
controlled trial 
41 patients aged 
3–17 years old 
with refractory 
seizures 
Patients were 
randomized to 
receive 20 weeks 
of high- or 
low-level vNS 
stimulation
High-level stimulation
Responder rate =16
Decrease in seizure frequency =-23 (increase)
Seizure freedom =0
Low-level stimulation
Responder rate =21
Decrease in seizure frequency =9
Seizure freedom =0Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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adjunctive treatment for management of intractable epilepsy 
was confirmed by a large number of open-label studies.24–27 In 
one study,24 19% of patients became “seizure-free” or “almost 
seizure-free” and 49% showed a “worthwhile improvement” 
post-VNS, according to the Engel Classification, a rating that 
takes the impact of seizures on daily life into account.
Pediatric populations
An RCT assessing the efficacy of VNS in children 
with refractory epilepsy was recently undertaken in the 
Netherlands.28 This study included 41 children aged 3–17 years   
with a diagnosis of either partial-onset or generalized epilepsy 
which was refractory to medical treatment. Patients were ran-
domized to receive either high- or low-output VNS. Baseline 
median seizure frequency was 2.1 seizures per day in the 
high-output group, and 0.9 seizures per day in the low-output 
group. Results showed a seizure reduction over 50% in 16% 
of the high-output and 21% of the low-output group with a 
weak negative correlation between age at onset and clinical 
response. The study also reported a positive outcome in terms 
of quality of life in both groups and the authors concluded that 
although the effects of VNS on seizure frequency in children 
may be limited, VNS remains a worthwhile treatment to be 
considered in children with refractory epilepsy.
In open-label studies assessing VNS in pediatric popu-
lations, responder rates varied between 22%29 and 90%.30,31 
Even though over 600 young patients have been recruited 
in prospective and retrospective studies so far, most of these 
studies have a small sample size, and a number of them 
focus on specific epilepsy syndromes or etiologies, such 
as Lennox–Gastaut syndrome32,33 or tuberous sclerosis.30 
Although the results of these studies overall suggest that VNS 
can be a useful treatment for refractory epilepsy in children, 
generalizing these findings to the broader pediatric population 
requires large-scale RCTs.
In conclusion, VNS has been shown to be effective in 
reducing seizure frequency in both adults and children with 
refractory epilepsy. Acute side effects occur in approximately 
3%–6% of patients, and include hoarseness, lower facial 
palsies, and infections. The most common long-term side 
effects include an alteration in voice, throat pain, and hoarse-
ness, which can occur in up to 40% of patients.17 Serious side 
effects such as asystole and bradycardia have been reported, 
but their incidence is lower than 0.1%.34
DBS
DBS involves the placement of one or more electrode 
leads into the brain parenchyma. These are connected to 
a battery-powered implanted pulse generator positioned 
in the subclavian space.35 Different deep brain structures 
are targeted depending on the condition to be treated. 
Stimulation of basal ganglia structures has been widely 
used in the management of treatment refractory move-
ment disorders such as Parkinson’s disease, dystonia, 
and tremor.36 DBS has also been used in the treatment of 
neuropsychiatric conditions such as depression, obsessive-
compulsive disorder, chronic pain, cluster headache, and 
Tourette syndrome.37,38
The exact mechanism of action of DBS in reducing sei-
zure frequency is unknown, and a number of theories have 
been proposed. It is unclear whether the stimulation from the 
implanted electrodes results in excitation or inhibition of the 
local neurons,39 or whether its effects are due to disruption 
of neuronal transmission.40 A number of RCTs (Table 2) 
and open-label trials have been conducted looking into the 
clinical efficacy of DBS as an adjunctive treatment in refrac-
tory epilepsy.
Thalamus
Several trials have assessed thalamic structures as targets 
for DBS, primarily focusing on either the anterior nucleus 
of the thalamus (ATN) or the centromedian nucleus of the 
thalamus (CMT).
The largest of these was the stimulation of the anterior 
nuclei of the thalamus for epilepsy (SANTE) RCT, which 
was undertaken in 2010.41 DBS electrodes were implanted 
in 110 patients, who were then randomized to receive either 
5 V or 0 V (control) stimulation intensity for 3 months. 
At baseline, patients in the DBS group had a median of 
18.4 seizures per month, compared to 20.4 per month in the 
control group. After this blinded period, all patients received 
stimulation from months 4 to 13, followed by a long-term 
open-label follow-up assessment. At the end of the blinded 
phase, a median decrease in seizure frequency of 40% was 
reported in the DBS group, compared to 16% in the control 
group. Two years after the implantation, median seizure 
reduction was 56% and responder rate was 54%. This trial 
provided significant support for the use of ATN DBS in 
refractory epilepsy, confirming results of previous, smaller 
scale trials.42–46
Seven open-label studies assessing ATN stimulation 
for treatment of refractory epilepsy have been undertaken 
to date, with sample sizes ranging between three and 
15 patients.42–48 Responder rates varied between 25%45 
and 100%44,46 and the reduction in seizure frequency 
ranged between 49%45 and 76%.46 Overall, these studies Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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consolidated the findings of the SANTE trial,41 providing 
supporting evidence that ATN DBS can be an effective 
treatment for refractory epilepsy.
Seven studies have been undertaken assessing stimula-
tion of the CMT in the treatment of epilepsy. The earliest 
study was a placebo-controlled crossover pilot trial involving 
seven patients in which seizure frequency was reduced by 
30%.49 More recent studies have been more encouraging with 
responder rates of 73%,50 92%,51,52 and 100%.53 In a study 
conducted on 13 patients with Lennox-Gastaut syndrome,52 
seizure frequency was reduced by 80%, with a responder 
rate of 92%. Overall, CMT DBS has been shown to be effec-
tive in treating refractory epilepsy, with particular benefit 
in management of generalized seizures.50,54,55 Large-scale 
RCTs are needed to provide robust evidence for the use of 
CMT DBS in clinical practice.
Table 2 Randomized-controlled trials for deep brain stimulation (DBS) in patients with refractory epilepsy
Study Study type Target  Participants Study protocol Measure of effect (%)
Fisher et al 
201041
Double-blind 
randomized 
controlled trial
Anterior 
nucleus of 
the thalamus 
110 patients aged 
18–65 years with 
refractory partial-
onset seizures 
Patients were randomized 
to receive 3 months of 
5 v or 0 v of stimulation, 
followed by an unblinded 
period of stimulation 
of up to 2 years
5 V stimulation
Responder rate = not reported
Decrease in seizure frequency =40
Seizure freedom =0
0 V stimulation (control)
Responder rate = not reported
Decrease in seizure frequency =16
Seizure freedom =1
Unblinded phase (at 2 years)
Responder rate =54
Decrease in seizure frequency =56
Seizure freedom (.6 months) =13
Tellez-Zenteno 
et al 200663
Double-blind 
multiple 
crossover 
randomized 
controlled trial
Axis of 
the left 
hippocampus 
Four patients aged 
24–37 years with 
refractory mesial 
temporal lobe 
epilepsy 
Patients were randomized 
to receive one of 
three treatment pairs, 
containing two treatment 
periods of 1 month “ON” 
and 1 month “OFF”
Stimulator “ON”
Responder rate =25
Decrease in seizure frequency =26
Stimulator “OFF”
Responder rate =25
Decrease in seizure frequency =–49 (increase)
Overall
Seizure freedom (at 4 years) =25
velasco et al 
200764
Double-blind 
randomized 
controlled trial
Hippocampal 
epileptic foci 
Nine patients 
aged 14–43 years 
with refractory 
partial-onset 
complex seizures 
Patients were randomized 
to either receive 
stimulation straight away 
after implantation, or 
a 1 month “OFF” period. 
This was followed by 
a follow-up period of 
18 months
Normal MRI
Responder rate =100
Decrease in seizure frequency = not reported
Seizure freedom (at 18 months) =80
Hippocampal sclerosis
Responder rate =100
Decrease in seizure frequency = not reported
Seizure freedom =0
McLachlan et al 
201065
Double-blind 
crossover 
randomized 
controlled trial
Axis of both 
hippocampi 
Two patients aged 
45 and 54 years 
with refractory 
mesial temporal 
lobe epilepsy 
Patients were randomized 
to receive a 3 month 
period where the 
stimulator was either 
“ON” or “OFF” 
Responder rate =0
Decrease in seizure frequency =33
Seizure freedom =0
wright et al 
198477
Double-blind 
multiple 
crossover 
randomized 
controlled trial
Cerebellum 12 patients aged 
20–38 years with 
severe, refractory 
epilepsy of 
unknown cause 
Patients were randomized 
to receive 2 months of 
continuous stimulation, 
2 months of intermittent 
stimulation, and 2 months 
of no stimulation, in any 
order
Responder rate =0
Decrease in seizure frequency = not reported
Seizure freedom =0
eleven patients reported improvement
velasco et al 
200578
Double-blind 
randomized 
controlled 
pilot study 
Cerebellum Five patients with 
refractory motor 
seizures
Patients were randomized 
to receive 3 months with 
the stimulator “ON” or 
“OFF”, after which, all 
were switched to “ON” 
for long-term follow-up 
Follow-up (at 24 months)
Decrease in seizure frequency
→ generalized tonic–clonic seizures =76
→ tonic seizures =57
Seizure freedom =0
Abbreviation: MRi, magnetic resonance imaging.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Basal ganglia
A small number of studies have been carried out assessing 
stimulation of basal ganglia structures as a treatment for 
refractory epilepsy, making the clinical efficacy of caudate 
nucleus DBS difficult to assess. Early studies showed that 
DBS of the caudate nucleus can reduce epileptic electrical 
activity,56–58 however, only one long-term clinical study has 
been undertaken to date.59 Of the 38 patients treated with 
stimulation of the head of the caudate nucleus, 35 (92%) 
showed a “worthwhile improvement” in mean seizure fre-
quency, which was eleven seizures per month at baseline.
The subthalamic nucleus (STN) has also been investigated 
as a potential target for DBS in epilepsy. We were able to 
identify only four studies on STN DBS for epilepsy, reflecting 
the paucity of scientific literature in this area. Two small open-
label studies44,60 and two case reports (each reporting on two 
patients)61,62 suggested that the use of STN DBS in refractory 
epilepsy is plausible, although the two patients followed-up 
in the study by Capecci et al62 showed no improvement and 
worsening of seizures after treatment. It is evident that this is 
an area where more research would be valuable, as the current 
evidence is lacking in statistical power.
Hippocampus
One of the most studied DBS targets in the treatment of 
refractory epilepsy is the hippocampus. Ten studies have been 
undertaken, including three small double-blind RCTs,63–65 all 
of which involved patients with refractory mesial temporal 
lobe epilepsy. In the first of these,63 four patients with a base-
line median seizure frequency of four per month, underwent 
implantation of a stimulating electrode into the left hippocam-
pus. Patients were randomized to receive three consecutive 
2-month treatment regimes, during which the stimulator was 
randomized to be “ON” for 1 month and “OFF” for another 
month. Outcomes were assessed at monthly intervals, and 
the authors reported a 15% median reduction in seizure 
frequency. They concluded that hippocampal DBS may be 
beneficial, and has few adverse effects, however their study 
did not show statistically significant improvements in seizure 
outcome, unlike other studies.
The second RCT64 followed up nine patients who had 
undergone electrode implantation into hippocampal foci, 
which were determined using diagnostic electrode studies. 
Five of the patients had normal brain magnetic resonance 
imaging (MRI) scans, and seizure frequency was reduced 
by over 95% in this group, from a baseline frequency of 
between 15 and 50 seizures per month. In the remaining 
four patients, who had hippocampal sclerosis documented by 
neuroimaging, seizure frequency was reduced by 50%–75%, 
from a baseline frequency of between 23 and 70 seizures per 
month. The authors concluded that electrical stimulation 
of the hippocampus improves seizure outcome in patients 
with hippocampal epileptic foci, without having detrimental 
effects on patient memory.
A third study65 used a double-blind, randomized, controlled 
crossover design to assess bilateral hippocampal DBS in two 
patients with refractory mesial temporal lobe epilepsy. After 
implantation, patients underwent a 3-month “baseline” period, 
during which there was no stimulation. This was followed by a 
3-month period during which the stimulator was either “ON” or 
“OFF” and all “ON” periods were followed by a 3-month “OFF” 
washout period to look for holdover effect. During stimulation, 
seizure frequency was decreased by 33%, and a decrease of 25% 
was maintained during the washout period, despite the lack of 
stimulation. The authors concluded that hippocampal DBS can 
have a positive effect on seizure frequency, both during and after 
stimulation; however, the effect sizes demonstrated in this study 
were not as large as in previous studies.
Seven further open-label studies have been undertaken 
since 2002, the majority of which demonstrated encourag-
ing results, albeit with small sample sizes. These studies 
were fairly homogeneous as far as samples and methods, 
and reported strikingly similar results. Published responder 
rates for these studies varied between 57%66 and 100%;67 
however, rates for five of the studies were very consistent, 
between 70% and 78%.68–72
Overall, there is a reasonable evidence base for the use 
of hippocampal DBS in the treatment of refractory mesial 
temporal lobe epilepsy. RCTs have been undertaken, albeit 
with small sample sizes that limit the generalization of the 
findings. However, encouraging results have been reported 
in both RCTs and open-label trials, indicating the need for 
further large trials.
Cerebellum
In the 1970s, Cooper et al73 studied the potential for cerebel-
lar DBS as a treatment for epilepsy, with some encouraging 
results. One study of 15 patients reported cerebellar stimula-
tion to be useful in two-thirds of the sample,74 while another 
study demonstrated a significant improvement in 62%.75 
These early observational pilot studies73–76 prompted further 
research to be carried out; however, there is still a lack of 
evidence in this area.
Two RCTs have been carried out assessing cerebellar 
DBS as a treatment for refractory epilepsy, with notably 
different results. The first trial was undertaken in 1984,77 Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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where 12 patients had two electrodes implanted into their 
cerebellum, after which they were randomized to a 6-month 
treatment regime. Each regime comprised of three 2-month 
periods during which the stimulator was either continuously 
firing, intermittently firing, or not firing at all. There was no 
significant decrease in seizure frequency, however, patients 
did report feeling an improvement during the trial.
The second, more recent, RCT was a small pilot study 
undertaken in 2005 to assess the effects of cerebellar DBS 
on seizure outcome in refractory epilepsy.78 Five patients 
underwent bilateral cerebellar electrode implantation, after 
which the stimulators were “OFF” for 1 month. After this, 
patients were randomized into two groups, in which stimu-
lators were either “ON” or “OFF” for 3 months. Following 
this, all stimulators were set to “ON” for the remainder of 
the study. During the initial double-blind phase, frequency 
of generalized tonic–clonic seizures decreased significantly 
in the group receiving stimulation compared to the control 
group (P=0.023). After both groups had received stimulation 
for 6 months, mean seizure rate had decreased to 41% of 
baseline levels. The authors concluded that cerebellar DBS 
may be an effective and safe treatment for refractory epilepsy, 
especially generalized tonic–clonic seizures.
While some positive results have been demonstrated, 
larger trials should be undertaken to estimate the potential 
benefit of cerebellar DBS, which appears to be a useful and 
safe treatment option for refractory epilepsy.
Overall, DBS has been shown to be effective in reduc-
ing seizure frequency in patients with refractory epilepsy. 
Evidence is strongest for stimulation of certain targets such 
as the ATN and the hippocampus, whereas other targets 
require further investigation in order to build more robust 
evidence. Although DBS has been shown to be a safe and 
well-tolerated treatment in most cases, the proportion of 
patients who achieved seizure freedom was either low or not 
reported at all. Further studies investigating rates of seizure 
freedom after DBS treatment may be useful, as absolute sei-
zure freedom is arguably a more important clinical outcome 
measure than decrease in seizure frequency in this patient 
population. The majority of large-scale data on the safety 
of DBS are available only for trials on movement disorders 
patient populations, and relatively little is known about 
possible disease-specific adverse effects in patients with 
epilepsy. Serious complications such as status epilepticus 
and sudden death have been reported, however these are 
rare.79 The most commonly reported adverse effects include 
bleeding, infection, mechanical complications, and neuro-
psychiatric changes.80–82
Responsive neurostimulation
RNS are a new method of implantable neurostimulation used 
to treat refractory epilepsy.83 RNS can detect seizure activity 
in the brain by monitoring electrocorticographic activity and 
deliver electrical stimulation directly to the seizure foci, in 
order to suppress seizure activity in a targeted way.84 This 
process is known as closed-loop stimulation. Implantation 
involves insertion of electrodes in the target area of the 
brain, which is then connected to a small device positioned 
under the skin.85
The results of a large RCT exploring RNS as a novel 
treatment strategy for refractory epilepsy were published 
in 2011.83 Responsive neurostimulators were implanted in 
191 adults with refractory partial epilepsy, and after 1 month 
the patients were randomized to receive either stimula-
tion in response to seizure activity (treatment group) or no 
stimulation (control group). Mean baseline seizure frequency 
rates did not vary between the two groups, where patients 
had an average of 1.2 seizures per day. Seizure outcomes 
were assessed over the 12-week blinded period, after which 
all patients received responsive stimulation as part of an 
84-week open-label continuation study. Seizure frequency 
was reduced by 38% in the treatment group compared to 
17% in the control group (P=0.012), and seizure reduction 
was maintained during the open-label period. The authors 
also found that treatment with RNS was associated with 
improvements in quality of life. Adverse effects reported 
included pain at the site of implantation, headache, seizure 
worsening, and memory impairment. The majority of adverse 
effects were self-limiting and mild, whereas severe side 
effects were rare.
A number of smaller open-label studies and case reports 
yielded results in line with those of this RCT. Median sei-
zure frequency reduction ranged between 41% and 76%, 
demonstrating the benefits of RNS in refractory seizures. 
These studies were carried out on small samples (between 
one and eight patients), and used a range of brain targets, 
including cortical and thalamic zones, as well as identified 
epileptogenic zones.86–88 Despite limitations in sample size 
and study methodology, these studies provided promising 
pilot data for the large RCT.83
Overall, RNS appears to be a promising technique 
for the treatment of refractory epilepsy; however, it has 
recently been highlighted that there is considerable room for 
improvement.89 In particular, potential options are currently 
being explored in order to improve the accuracy of the seizure 
prediction method.90 Furthermore, the electrical stimula-
tion parameters need to be standardized, as a wide range of Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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settings were used in the open-label studies. Standardization 
of study methodology will allow the development of clinical 
guidelines incorporating this implantable neurostimulation 
device. In conclusion, RNS is a new method of implantable 
stimulation that has shown initial improvements in seizure 
outcome for patients with refractory epilepsy. In order to 
strengthen the existing evidence base, further large-scale 
RCTs need to be carried out.
Conclusion
Implantable neurostimulation devices, including VNS, DBS, 
and RNS, offer promising avenues for reduction in seizure 
frequency in patients with refractory epilepsy, a group of 
patients that present high morbidity, mortality, and reduced 
quality of life. Seizure freedom appears to be a less realistic 
expectation according to published data, possibly reflecting 
selection bias. Furthermore, average seizure frequencies 
before and after treatment are inconsistently reported across 
the reviewed studies, making it difficult to fully appreciate 
the exact magnitude of percentage decreases. Future studies 
will certainly continue to refine our ability to determine the 
impact of these treatment options on clinical practice. Further 
research should be carried out to explore other potential ben-
efits of implantable neurostimulation devices; for example, 
reducing seizure severity. This may include prevention of 
spread of epileptic discharge or the occurrence of loss of 
consciousness across both partial-onset and generalized 
seizures.91–95 A further aspect to make this therapeutic option 
appealing is the relatively low prevalence of serious adverse 
effects, a factor contributing to significant improvement in 
health-related quality of life.
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